Nuwellis

NUWE

Börsenwert 1,74 Mio. $

MINNEAPOLIS, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will convene a Medical & Nursing Advisory Board on November 18–19, 2026, to support the continued development of Vivian™, the Company's next-generation pediatric continuous renal replacement therapy (CRRT) platform. Vivian is under development for children as small as 2.5kg and it incorporates multiple fluid management therapies in one platform.

MINNEAPOLIS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced its participation in four leading medical conferences in October spanning pediatrics, critical care, and heart failure. Across the events, Nuwellis will engage directly with clinicians on the challenge of fluid overload and the role of its Aquadex SmartFlow® system in providing precise, controlled fluid removal for patients who require individualized fluid management.

Year-to-date console sales exceed full-year console sales in seven of the past 10 years, putting Nuwellis on pace for one of its strongest years in console placements Year-to-date console sales exceed full-year console sales in seven of the past 10 years, putting Nuwellis on pace for one of its strongest years in console placements

Experienced medical device quality and regulatory leader brings 13 years of experience supporting quality systems, regulatory compliance, audits and product development Experienced medical device quality and regulatory leader brings 13 years of experience supporting quality systems, regulatory compliance, audits and product development

MINNEAPOLIS, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, highlights continued progress under its financial efficiency strategy, including significant gross margin improvement, sustained product quality and supply performance, and further optimization of its cost structure.

Agreement expands Nuwellis' pediatric and critical care portfolio and provides a milestone-based pathway to U.S. distribution Agreement expands Nuwellis' pediatric and critical care portfolio and provides a milestone-based pathway to U.S. distribution

Nuwellis, Inc. (NUWE) Q2 2026 Earnings Call Prepared Remarks Transcript

Recent capital raise and warrant exercises extend cash runway through second quarter of 2027 Conference call begins at 9:00 a.m. Eastern time today MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the three and six months ended June 30, 2026.

MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Dale Brady as Principal R&D Engineer. Brady brings more than 25 years of medical device leadership experience in research and development, operations, manufacturing, quality systems and commercialization, with a proven track record of advancing innovative products from concept through commercial launch.

Development initiatives to strategically extend Aquadex® platform capabilities for future immunomodulation, extracorporeal blood purification, and advanced critical care therapies Development initiatives to strategically extend Aquadex® platform capabilities for future immunomodulation, extracorporeal blood purification, and advanced critical care therapies